Legal & General Group’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-51,763
| Closed | -$1.11M | – | 3429 |
|
|
2026
Q1 | $1.11M | Sell |
51,763
-11,905
| -19% | -$168K | ﹤0.01% | 2109 |
|
|
2025
Q4 | $593K | Buy |
63,668
+6,804
| +12% | +$56.8K | ﹤0.01% | 2369 |
|
|
2025
Q3 | $401K | Hold |
56,864
| – | – | ﹤0.01% | 2505 |
|
|
2025
Q2 | $370K | Sell |
56,864
-3,701
| -6% | -$25.5K | ﹤0.01% | 2523 |
|
|
2025
Q1 | $480K | Buy |
60,565
+2,942
| +5% | +$31.7K | ﹤0.01% | 2408 |
|
|
2024
Q4 | $730K | Buy |
57,623
+1,359
| +2% | +$18.9K | ﹤0.01% | 2333 |
|
|
2024
Q3 | $784K | Buy |
56,264
+1,087
| +2% | +$15.5K | ﹤0.01% | 2315 |
|
|
2024
Q2 | $760K | Buy |
55,177
+1,753
| +3% | +$25.6K | ﹤0.01% | 2286 |
|
|
2024
Q1 | $883K | Sell |
53,424
-67
| -0.1% | -$1K | ﹤0.01% | 2233 |
|
|
2023
Q4 | $781K | Sell |
53,491
-239
| -0.4% | -$2.9K | ﹤0.01% | 2284 |
|
|
2023
Q3 | $659K | Buy |
53,730
+4,630
| +9% | +$60.4K | ﹤0.01% | 2327 |
|
|
2023
Q2 | $586K | Buy |
49,100
+46,515
| +1,799% | +$608K | ﹤0.01% | 2409 |
|
|
2023
Q1 | $34.6K | Hold |
2,585
| – | – | ﹤0.01% | 2934 |
|
|
2022
Q4 | $55.6K | Hold |
2,585
| – | – | ﹤0.01% | 2938 |
|
|
2022
Q3 | $52K | Buy |
2,585
+561
| +28% | +$11.9K | ﹤0.01% | 2963 |
|
|
2022
Q2 | $36K | Sell |
2,024
-159
| -7% | -$1.64K | ﹤0.01% | 3069 |
|
|
2022
Q1 | $22K | Buy |
2,183
+1,156
| +113% | +$15.3K | ﹤0.01% | 3210 |
|
|
2021
Q4 | $17K | Hold |
1,027
| – | – | ﹤0.01% | 3322 |
|
|
2021
Q3 | $24K | Buy |
+1,027
| New | +$24.6K | ﹤0.01% | 3209 |
|
Other funds holding DAWN
Legal & General Group's DAWN Position: Q2 2026 in Review
Legal & General Group sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 51,763 shares — an estimated $1.11M sold.
Legal & General Group first reported a position in DAWN in Q3 2021 and held it in 19 quarters. The position peaked at $1.11M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Legal & General Group reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Legal & General Group sold 51,763 Day One Biopharmaceuticals shares in Q2 2026, an estimated $1.11M.
- Legal & General Group first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 19 quarters.
- Legal & General Group's Day One Biopharmaceuticals position peaked at $1.11M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.